First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third-line treatment is often needed to better manage the disease. The CHF market is heavily genericized, and prescribers have many drugs and drug classes from which to choose, creating a high barrier to uptake for novel branded agents, such as Novartis’s Entresto and Amgen’s Corlanor. This Treatment Algorithms report offers insight into the prescribing patterns across all CHF patients in the United States.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CHF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CHF patients?
- How have Entresto and Corlanor been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of CHF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of CHF patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Novartis, AstraZeneca, Amgen
Key drugs: SGLT-2 inhibitors, Entresto, ACE inhibitors
- Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Chronic Heat Failure US March 2021
- Treatment Algorithms CDA Chronic Heart Failure US 2021 Dashboard
Author(s): Gideon Heap
Gideon Heap, M.Sc., is a director on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at DRG, part of Clarivate. In addition to authoring several reports, he has conducted company strategy and portfolio analyses for DRG’s Company & Drug platform. He holds a master’s degree in biochemistry from the University of Nottingham.